A Gene Hunting Study for Familial Papillary Thyroid Cancer

Description

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.

Conditions

Thyroid

Talk to us

Study Overview

On this page

Study Details

Study overview

The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.

A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated

A Gene Hunting Study for Familial Papillary Thyroid Cancer

Condition
Thyroid
Intervention / Treatment

-

Contacts and Locations

Columbus

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with a diagnosis of PTC and a family history of PTC in 3 or more living relatives
  • * Affected and unaffected family members of the proband\*
  • * For familial cases (families with 4 or more cases of PTC), participation will be offered to all living family members with PTC or benign thyroid disease as well as selected unaffected first and second degree relatives. Participation may also be offered to spouses when needed for analyzing parent/offspring samples.
  • * Known germline predisposition (ex: pathogenic PTEN variant)
  • * Non-English speaking

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ohio State University Comprehensive Cancer Center,

Matthew Ringel, MD, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

2026-12